Jayamas Medica Industri (OMED) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Jayamas Medica Industri IDR 215, price IDR 206, upside +4.6%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Jayamas Medica Industri for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
46‑month range 143.80 IDR – 303.86 IDR · fair‑value band 152.88 IDR – 297.48 IDR · the 206.00 IDR price screens below the 215.46 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Jayamas Medica Industri in your weekly email
Every Wednesday you see whether Jayamas Medica Industri is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Jayamas Medica Industri Tbk manufactures and sells medical devices in Indonesia, the United States of America, and South America. The company operates through three segments: Manufacturing, Distribution, and Retail.
Show more
PT Jayamas Medica Industri Tbk manufactures and sells medical devices in Indonesia, the United States of America, and South America. The company operates through three segments: Manufacturing, Distribution, and Retail. It offers medical disposables and consumables comprising medical gloves, syringes, masks, gauze, bandages, urine bag, foley catheter, alcoholic tissue, etc.; antiseptic and disinfectant fluids, povidone iodine, medical alcohol, Hdsol or blood cleansing liquid, etc.; and diagnostics and equipment, such as patient monitor, vital signs monitor, ECG reader, syringe pump, infusion pump, blood pressure monitors, oximeter, fingertip pulse oximeters etc. The company also provides walking aids and rehabilitation care products, including wheelchairs, crutches, walkers, arm slings etc.; biotechnology and laboratory products, such as pregnancy test, PCR test, blood collection tube, PCT tube, chemical reagents, etc; and hospital furniture products comprising patient bed, bed side cabinet, children's patient bed, and operation lamp, as well as wound care products which include plasters, cotton, sterile gauze, etc. In addition, the company engages in warehousing and storage activities; and engages in the manufacturing, selling, and repairs and maintenance of medical devices. It retails medical supplies and equipment through Medicom stores and online platforms. PT Jayamas Medica Industri Tbk was founded in 2000 and is headquartered in Sidoarjo, Indonesia. PT Jayamas Medica Industri Tbk operates as a subsidiary of Pt. Intisumber Hasilsempurna.
Stock analysis
Jayamas Medica Industri (OMED) currently trades at 206.00 IDR, while our model-based Fair Value estimate is 215.46 IDR, implying the stock looks roughly 4.4% fairly valued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 260.62 IDR per share, and 15 of the 26 models we run sit above the 206.00 IDR price.
Bear case: the Dividend Discount group reads lowest at 42.59 IDR, and 11 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: 152.88 IDR (bear) to 297.48 IDR (bull), the price of 206.00 IDR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Jayamas Medica Industri reported revenue of 2.1T IDR in FY2025 versus 2.2T IDR in FY2021, a compound −1.9%/yr. Reported net income was 367B IDR in FY2025, compounding −10.1%/yr from FY2021.
Key figures
Market cap 5.6T IDR (≈ $557M) · P/E ratio 14.2 · P/S ratio 2.52 · EPS (TTM) 14.52 IDR · Dividend yield 1.8% · Net margin 17.8% · Return on equity 14.6% · Return on assets (EBIT) 18.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at 5%, OMED screens cheaper than that median.
Fair Value models
Bear 152.88 IDRFair Value 215.46 IDRBull 297.48 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (10.62 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+9.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−6.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.2%
Dividend (yield on the price)1.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.43% → 19%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about +7.5% a year for the price.
Compare Jayamas Medica Industri with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside+5% · Above median
Profitability
Return on equity (TTM)15% · Top 25%
Return on assets9% · Top 25%
Net margin (TTM)18% · Top 25%
Operating margin (TTM)20% · Top 25%
Growth and dividend
Revenue growth31% · Top 25%
Dividend yield (TTM)1.8% · Above median
Balance sheet
Debt / equity0.07× · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jayamas Medica Industri Fair Value". https://www.fairvalue-calculator.com/stock/OMED
Frequently asked questions
Is Jayamas Medica Industri (OMED) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 215.46 IDR versus a price of 206.00 IDR, about +5% upside (fairly valued).
What is the fair value of OMED?
Our model-based fair value for Jayamas Medica Industri is 215.46 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 206.00 IDR.
What is the quality score of OMED?
Jayamas Medica Industri has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jayamas Medica Industri (OMED)?
Our model-based price target is the fair value of 215.46 IDR (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 152.88 IDR, optimistic scenario 297.48 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Jayamas Medica Industri stock forecast for 2026?
Our models put fair value at 215.46 IDR, about +5% upside versus a price of 206.00 IDR (fairly valued). Cautious scenario 152.88 IDR, optimistic scenario 297.48 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Jayamas Medica Industri (OMED)?
Jayamas Medica Industri reported trailing-twelve-month revenue of about 2.2T IDR (latest available figure, as of Sep 24, 2026).
Does Jayamas Medica Industri pay a dividend?
Jayamas Medica Industri currently shows a dividend yield of about 1.75% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Jayamas Medica Industri (OMED)?
For today's price to be fair in a discounted-cash-flow model, Jayamas Medica Industri would have to grow free cash flow by +10.3 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of OMED use?
Our models discount Jayamas Medica Industri at 12.0 %: a base by market capitalisation (small), damped by beta 0.10, country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jayamas Medica Industri that is +10.3 % per year a year over ten years, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has Jayamas Medica Industri (OMED) delivered so far?
Over the past 5 years revenue at Jayamas Medica Industri grew +0.7 % a year. The price currently implies +10.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jayamas Medica Industri (OMED) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Jayamas Medica Industri (+10.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jayamas Medica Industri (OMED)?
The free-cash-flow yield on the price is 5.01 %: that much free cash flow Jayamas Medica Industri produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jayamas Medica Industri (OMED)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jayamas Medica Industri it is 215.46 IDR per share (as of Sep 24, 2026), against a price of 206.00 IDR. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Jayamas Medica Industri stock overvalued or undervalued in 2026?
As of Sep 24, 2026, OMED trades below its calculated fair value: price 206.00 IDR, fair value 215.46 IDR, a gap of about +5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OMED?
No. The price is what the market pays today (206.00 IDR); the fair value is what the company's own numbers justify (215.46 IDR). For Jayamas Medica Industri the two are 9.46 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Jayamas Medica Industri worth?
The market values Jayamas Medica Industri at about 5.6T IDR (market capitalisation, as of Sep 24, 2026). Per share that is 206.00 IDR; our models calculate a fair value of 215.46 IDR per share.
What do the bullish and bearish scenarios say about OMED?
Our models span a range for Jayamas Medica Industri: cautious scenario 152.88 IDR, base 215.46 IDR, optimistic 297.48 IDR per share (as of Sep 24, 2026, price 206.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of OMED?
Jayamas Medica Industri trades at a price-to-earnings ratio of 14.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 215.46 IDR is built from several models across several years. Other multiples: P/B 2.1, P/S 2.5, EV/EBITDA 9.1.
How solid is the balance sheet of Jayamas Medica Industri (OMED)?
Balance-sheet figures for Jayamas Medica Industri (as of Sep 24, 2026): return on equity 14.6%, debt of 0.07 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is OMED from its 52-week high?
Jayamas Medica Industri trades at 206.00 IDR, about 32% below its 52-week high of 303.86 IDR and 14% above the low of 181.00 IDR (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 215.46 IDR is for.
Which stocks are comparable to Jayamas Medica Industri?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jayamas Medica Industri stock attractive at the current price?
The data as of Sep 24, 2026: price 206.00 IDR, calculated fair value 215.46 IDR (+5%), Quality Score 69/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OMED calculated?
We run Jayamas Medica Industri through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 215.46 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Jayamas Medica Industri currently trades 5 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jayamas Medica Industri (OMED)?
The closing price on Sep 23, 2026 was 206.00 IDR. Our model-based fair value is 215.46 IDR, about +5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jayamas Medica Industri right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (152.88 IDR to 297.48 IDR) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Jayamas Medica Industri
How large is the market capitalisation of Jayamas Medica Industri (OMED)?
The market capitalisation of Jayamas Medica Industri is 5.6T IDR (≈ $557M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jayamas Medica Industri (OMED)?
The price-to-sales ratio of Jayamas Medica Industri is 2.52 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jayamas Medica Industri (OMED)?
Earnings per share at Jayamas Medica Industri are 14.52 IDR (price ÷ EPS = P/E 14.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jayamas Medica Industri (OMED)?
The dividend yield of Jayamas Medica Industri is 1.8% (payout 24.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jayamas Medica Industri (OMED)?
The net margin of Jayamas Medica Industri is 17.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jayamas Medica Industri (OMED)?
The return on equity (ROE) of Jayamas Medica Industri is 14.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jayamas Medica Industri (OMED)?
On an EBIT basis the return on assets of Jayamas Medica Industri is 18.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jayamas Medica Industri (OMED)?
The operating margin of Jayamas Medica Industri is 19.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jayamas Medica Industri (OMED)?
Revenue at Jayamas Medica Industri is growing +31.2% versus a year earlier (3y avg +5.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jayamas Medica Industri (OMED)?
Earnings per share at Jayamas Medica Industri are growing +35.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Jayamas Medica Industri (OMED) hold?
Jayamas Medica Industri holds more cash than debt, 1.1T IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Jayamas Medica Industri in the live analysis
One click puts Jayamas Medica Industri on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
